52 week high

52 week high American Italian Pasta (AIPC): 52 week rang of $4.26 to $26.61. Current trading at $26.61. Shares of American Italian Pasta (AIPC) have had a monster run since March of 2008 up over 400% versus a decline in the S&P 500 of about 45%. American Italian Pasta trades with a forward P/E of 12.10 Price over Sales (PS ratio) of 0.95, and Enterprise Value/EBITDA of 8.269. American Italian Pasta is the largest U.S producer of dry pasta with Wal-Mart acting as their largest customer on the retail side. On Dec. 11th they reported fourth-quarter earnings of 36 cents a share, up from 10 cents the prior year. Full-year sales rose 43% to $569 million. Profit improved to 99 cents a share from 28 cents in 2007 and a loss of $1.65 in 2006. In mid-September, former Chief Executive Timothy Webster and former Chief Financial Officer Warren Schmidgall pleaded guilty to one count each of wire fraud. Three other officers were charged and penalized. However, with completely new management, a new business plan, it makes sense that Chief Executive Jack Kelly recently said “Part of any re-emergence story, of course, is closing the chapter on past issues,"

52 week low Anadys Pharmaceuticals (ANDS): 52 week range of $1.41 to $5.98. Currently trading at $5.81. Shares of Anadys Pharmaceutical (ANDS) are up around 250% year-to-date alone versus a decline in the S&P 500 of 5.56% On January 8th shares of Anadys gapped higher by 115% as the company released the first antiviral activity data on its lead hepatitis C drug The key point here: 8 patients with hepatitis C treated with twice-daily dose of Anadys ANA598 hepatitis drug reported an average reduction of more than 99% in the level of virus after just three days of treatment On December 2nd 2008, the Food and Drug Administration announced that the FDA is giving Anadys ANA598 hepatitis C drug a fast-track review. According to the FDA “Under the program, companies can submit their applications in piecemeal fashion instead of all at once, company scientists also can schedule special meetings to discuss their application with regulators” Anadys claims that hepatitis C affects about 3.2 million people in the U.S and 170 million people worldwide

52 week low Abiomed (ABMD): 52-week range of $9.00 to $20.07. Currently trading at $8.97. Shares of Abiomed Inc which makes heart pumps is down about 45% year-to-date versus a decline in the S&P 500 of 5.56% On February 5th Abiomed reported a fourth-quarter loss on a per share basis of -$0.21 versus a loss of -$0.26 per share a year ago. Abiomed also guided 2009 revenue towards the low end of their $75 million to $80 million dollar range Abiomed which now trades at 4x 2009 revenue said it sold 55 Impella 2.5 Cardiac Assist Device systems during the fourth quarter, bringing total U.S. sales to 163. This system allows surgeons to implant a device that maintains blood flow in heart-failure patients during and after surgery. Revenue from Impella sales more than doubled to $8.9 million Abiomed has $51 million dollars in cash, and zero debt

52 week low Advisory Board Company (ABCO): 52 week range of $16.80 to $58.01. Currently trading at $16.80. Shares of Advisory Board are down over 70% since January 2008 versus a decline in the S&P 500 of about 45% Advisory Board Company provides best practices research, decision support tools to the health care industry. Advisory Board which reports after the close on Monday, trades with a forward P/E of 11.48, and Enterprise Value over EBITDA of 5.742

52 week low